#Sustainability #India #Mumbai #Piramal Pharma #SP Global CSA

Piramal Pharma's Outstanding Sustainability Achievement

Piramal Pharma Limited (PPL) is making headlines with a remarkable score of 63 on the 2025 SP Global Corporate Sustainability Assessment (CSA), marking a significant 15% increase from last year’s score of 55. This annual evaluation assesses thousands of companies worldwide, focusing on sustainability practices across various criteria, including environmental, social, and governance (ESG) metrics.

The SP Global CSA stands out as one of the most respected frameworks globally for assessing sustainability. Companies achieving high scores tend to enhance their reputation with customers and attract international investors by demonstrating their commitment to responsible practices. PPL's surge in score places it in the 91st percentile of the pharmaceutical industry, reflecting its significant commitment to advancing sustainable practices.

One foundational aspect of PPL's success can be attributed to initiatives like the installation of a 240 kWp rooftop solar system in Digwal in April 2024. This system was designed to bolster on-site renewable energy generation, producing approximately 607 GJ of renewable power in FY2025, which led to a reduction of 123 tCO₂e emissions. These steps underline PPL's broader commitment to expanding the use of clean energy within its operations.

The SP Global CSA evaluates companies based on critical dimensions related to ESG performance, governance maturity, and long-term value creation. It has become an essential database for corporations striving to measure and improve their sustainability strategies against both competitors and industry benchmarks. Additionally, a higher CSA score can significantly bolster a company's appeal to customers and investors alike.

PPL’s initiative for sustainable growth is grounded in four strategic pillars: business resilience, excellence, responsible operations, and stakeholder engagement. By focusing on these areas, PPL enhances its operational effectiveness and demonstrates a persistent commitment to socially responsible practices that benefit not just the company but also its partners, patients, and the environment.

Peter DeYoung, CEO of Piramal Pharma, commented on the company’s achievement, stating, “Our progress in the SP Global CSA underscores our unwavering commitment to responsible operations and sustainable growth. As we pursue our expansion, we remain dedicated to excellence in all aspects of our work, ensuring it contributes to a healthier future for all.” Following this commendable trajectory, PPL aims to further its sustainable development efforts and assist its partners in enacting positive changes within the industry.

Piramal Pharma Limited is not just a leader in pharmaceuticals but also a key player in responsible healthcare solutions. With a broad offering of differentiated products and services from its 17 global development and manufacturing sites, PPL engages in a diverse range of sectors including Piramal Pharma Solutions which specializes in contract development and manufacturing, Piramal Critical Care focusing on complex hospital generics, alongside Piramal Consumer Healthcare dedicated to consumer wellness products. It is also strategically involved with Abbvie Therapeutics India Private Limited, a joint venture poised as a market leader in ophthalmology therapies.

As PPL builds upon the momentum gained from the SP Global CSA, it is well-positioned to continue enhancing its sustainability profile and contribute positively to the pharmaceutical landscape. This ongoing commitment not only reinforces PPL’s operational foundations but also sets a benchmark in the industry, promoting the essential shift towards more sustainable business practices in healthcare.

To learn more about Piramal Pharma and its endeavors in sustainable healthcare, visit Piramal Pharma.